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Abstract
Germline mutations are a driving force behind genome evolution and genetic disease. We 
investigated genome-wide mutation rates and spectra in multi-sibling families. Mutation rate 
increased with paternal age in all families, but the number of additional mutations per year 
differed more than two-fold between families. Meta-analysis of 6,570 mutations showed that 
germline methylation influences mutation rates. In contrast to somatic mutations, we found 
remarkable consistency of germline mutation spectra between the sexes and at different paternal 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Correspondence should be addressed to M.E.H. (meh@sanger.ac.uk).$UK10K membership described in Supplementary Note
Author Contributions
R.R., A.W., and M.E.H. developed analytical and/or analysed sequencing data, R.R. performed mutation rate estimate, family 
comparison, germline mosaicism and validation, A.W. meta-analysed DNMs for mutational spectrum, methylation status, S.J.L., and 
R.J.H., contributed towards phasing and detection and validation of DNMs, L.B.A. performed mutational signature analysis, S.A.T. 
contributed to whole genome data analysis, A.D., A.M., D.P., and B.S. provided blood samples of SFHS, M.R.S. advised on 
mutational processes, UK10K Consortium, contributed sequences for meta-data analysis, R.R., A.W., M.E.H. wrote the manuscript, 
M.E.H. supervised the project. Authors have no competing financial interests.
Competing financial interests
The authors declare no competing financial interests.
URLs
UK10K, http://www.uk10k.org; Signatures of Mutational Processes in Human Cancer, http://cancer.sanger.ac.uk/cosmic/signatures; 
Generation Scotland, http://www.generationscotland.org/; UCSC Lift Genome Annotations, https://genome.ucsc.edu/cgibin/
hgLiftOver; Avon Longitudinal Study of Parents and Children, http://www.bristol.ac.uk/alspac/; TwinsUK, http://www.twinsuk.ac.uk/; 
Ensemble, comparative genomics, http://www.ensembl.org/info/genome/compara/index.html; UCSC ENCODE composite track, 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encodeDCC/wgEncodeHaibMethylRrbs/
Accession codes
Whole genome sequencing data are accessible via the European Genome-phenome Archive (EGA) under accession 
EGAD00001001214
Europe PMC Funders Group
Author Manuscript
Nat Genet. Author manuscript; available in PMC 2016 June 14.
Published in final edited form as:
Nat Genet. 2016 February ; 48(2): 126–133. doi:10.1038/ng.3469.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
ages. 3.8% of mutations were mosaic in the parental germline, resulting in 1.3% of mutations 
being shared between siblings. The number of these shared mutations varied significantly between 
families. Our data suggest that the mutation rate per cell division is higher during both early 
embryogenesis and differentiation of primordial germ cells, but is reduced substantially during 
post-pubertal spermatogenesis. These findings have important consequences for the recurrence 
risks of disorders caused by de novo mutations.
Introduction
Mutations have manifold consequences, from driving evolution to causing disease. DNA 
damage can have exogenous causes such as ionizing radiation and mutagenic chemicals or 
endogenous causes such as oxidative respiration and errors in DNA replication1,2. Both 
endogenous and exogenous damage are restored by DNA repair pathways, which are highly 
conserved in mammals2. However, damage repair pathways are not perfect and de novo 
mutations (DNMs) occur in every generation.
Knowledge of the rates and mechanisms by which germline mutations arise has diverse 
applications, from empowering the discovery of the genetic causes of rare disorders3, to 
dating critical periods in human evolution4. Based on whole-genome sequencing studies of 
trios the average generational mutation rate of single base substitutions in humans has been 
estimated5-9 to be ~1-1.5×10−8.
In 1947, Haldane noted that the mutation rate of the hemophilia gene is significantly higher 
in men than in women10. Recent genome sequencing studies confirmed Haldane’s 
observation that the male germline is more mutagenic5-8,11. On average, each additional year 
in the father’s age at conception results in ~2 additional DNMs in the child6. 
Correspondingly, the risk of dominant genetic disorders in the child increases with 
increasing paternal age12,13. The most likely cause of the paternal age effect is the increasing 
number of cell divisions in the male germline14. While oocytes are produced early in a 
woman’s life and have a fixed number of genome replications, spermatogenic stem cells 
undergo continuous genome replication throughout a man’s life. It has been estimated that 
the male germline experiences 160 genome replications in a 20 year old male, rising to 610 
genome replications in a 40 year old male15.
Mutation rate depends on local nucleotide context. Moreover, studies of somatic mutations 
in cancer have shown that the observed mutation spectra can be decomposed into different 
‘mutational signatures’ that reflect particular cellular contexts of exogenous and endogenous 
mutagen exposure and the efficiency of different DNA repair pathways16.
The germline comprises a lineage of different cellular contexts, from the zygote to the 
gamete17 (Supplementary Figure 1). Post-zygotic mutations can potentially lead to germline 
mosaicism. Observing apparent DNMs shared between siblings – predominantly in studies 
of dominant disorders – has provided direct evidence for germline mosaicism18. While 
recent studies have determined the average germline mutation rate and estimated the average 
paternal age effect, a deeper understanding of germline mutational rates, spectra and their 
underlying mutational processes remains elusive. For example, it is not known whether 
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mutation spectra differ between paternal and maternal germlines, nor whether mutation rates 
and spectra vary significantly between families, or whether different stages of the cellular 
lineage between zygote and gamete differ in their mutation rates and spectra.
Here, we investigated human germline mutations within and between multi-sibling families. 
This allowed us to compare mutation rates and spectra between families and to detect 
instances of post-zygotic mosaicism. We also investigated mutational processes and spectra 
more broadly by combining our data with previously published datasets.
Results
Family-specific paternal age effects
We sequenced the genomes of three multi-sibling families (Figure 1). We discovered and 
validated 768 DNMs across the three families, with an average of 64 per child (range 43–84, 
Supplementary Table 1). When taking into account genomic regions inaccessible to our 
analyses (Methods), the average number of mutations per individual increases to 76.9. This 
adjusted number of mutations is equivalent to an average mutation rate of 1.28×10−8 (95% 
confidence interval 1.13–1.43×10−8) at a mean paternal age of 29.8 years. In the following 
analyses, we used the adjusted number of mutations.
We determined the parental origin of 399 DNMs, 311 of which (78%) were of paternal 
origin (Figure 1). Our data confirm the paternal age effect. Taking all families together, the 
number of DNMs increases with the fathers’ age by 2.87 per year (95% confidence interval 
2.11–3.64). In all three families, there is a 12–13 year gap between the youngest and oldest 
siblings, which enabled us to estimate the parental age effect for each family separately. The 
correlation between paternal age and the number of DNMs in the child was even stronger 
when each family is considered separately (Figure 2). The parental age effect for family 244, 
603, and 569 is 1.46 (95% confidence interval 1.15–1.78), 3.27 (CI 2.07–4.47), and 3.65 (CI 
1.52–5.77) mutations per year, respectively. Overall, a model that takes both paternal age 
and family into account performs significantly better in predicting the number of mutations 
in the offspring than a model that only considers paternal age (p = 0.020, Analysis of 
Variance).
Germline mosaicism in parents
Mutations that occur during early development can lead to mosaicism in germline and/or 
somatic tissues. Germline mosaic mutations in parents could be passed on to more than one 
child. We used two orthogonal approaches to identify potential parental germline mosaic 
DNMs in our multi-sibling family sequencing data, by deeply sequencing every validated 
DNM in every individual in all three pedigrees to a mean depth of 567X per individual 
(Methods).
First, we identified 10 validated DNMs that are shared between at least two siblings in the 
same family, which are clearly not constitutively heterozygous in either parent (alternate 
allele fraction <10%). Based on this, the probability of any germline mutation being shared 
between two siblings is 1.3% (Supplementary Table 2).
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Second, by identifying sites with a significant excess of alternative (ALT) reads in the DNA 
from a single parent (Methods), we distinguished sites among the validated DNMs that were 
potentially mosaic at low levels in parental blood (Figure 3B, Table 1, Supplementary Figure 
2). This approach identifies germline mutations mosaic in at least one parental somatic 
tissue, and thus most likely occurred during early embryonic development of the parent, 
prior to the separation and proliferation of the germline and the soma, and consequently are 
mosaic in both tissues. We attempted further experimental validation of the candidate mosaic 
sites using orthogonal amplification and sequencing technologies (Methods). Taking these 
independent experiments together, we identified 25 DNMs with excess parental ALTs, 
ranging from 0.6% to 10% of the reads, with a median of 3%. We modeled our statistical 
power to detect parental somatic mosaicism (Figure 3A) and conclude that we have ~80% 
power to detect a mosaic variant present in 1% of parental blood cells and ~90% power to 
detect a variant in 2% of parental blood cells.
Six of the ten DNMs shared among siblings also exhibited parental somatic mosaicism, 
which is a significant enrichment (p=4.6e-7, Fishers Exact Test). Four DNMs were shared 
among siblings without excessive ALTs in parental blood. Hence they either occurred after 
the separation of germline and soma, or had parental somatic mosaicism below detectable 
levels. In total, 29 of validated DNMs have evidence of parental germline mosaicism (Table 
1). Correcting for our incomplete power to detect mosaic mutations (Figure 3A), suggests 
that 4.2% of germline mutations may be may be mosaic in >1% of parental blood cells 
(Methods).
64% (16/25) of the parental mosaic DNMs were maternal in origin. This is compatible with 
a 1:1 ratio of paternal and maternal somatic mosaicism but represents a significantly 
different ratio of parental origins compared to paternal bias observed in all 768 DNMs 
(p=7.7e-6, binomial test). There is not likely due to differential sequencing-coverage 
between mothers and fathers (Supplementary Figure 3).
Germline mutational spectra
We compiled a catalogue of 6,570 high confidence DNMs from 109 trios based on six 
different sources, including the families we sequenced for this project (Supplementary Table 
3). All DNMs were called from whole-genome sequencing data. For 10% of the mutations, 
data on parental origin were available.
We used this catalogue to evaluate evidence for distinct germline mutational processes. Low 
resolution mutational spectra, which we define as the relative frequency of the six possible 
point mutations confirm the expected preponderance of transitions over transversions 
(Figure 4A). There was no significant difference between the spectra of maternal and 
paternal mutations (p = 0.19, Chi-squared test; Figure 4B). Even though there is a significant 
difference in the magnitude of the paternal age effect between the three families, there is no 
significant difference between the mutational spectra of the three families (p = 0.925, Chi-
squared test, nor between the spectra of DNMs of children born to young and old fathers (p 
= 0.83, Chi-squared test; Figure 4C).
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As an independent assessment of potential differences in maternal and paternal mutation 
spectra, we contrasted variants identified on chrX and chrY in a genome-wide sequencing 
dataset based on 2,453 individuals from the UK10K project. All variation on chrY arose in 
the male germline, whereas variation on chrX is generated in both the maternal and paternal 
germline. We observed that only rare variants faithfully recapitulate the mutation spectra 
observed in de novo mutations19, as the ratio of C:G>T:A and T:A>C:G transitions 
decreases dramatically with increasing derived allele frequency, most likely because of 
biased gene conversion20 (Supplementary Figure 4). We did not observe any statistically 
significant difference (p = 0.10, Chi-squared test) in chrX and chrY mutation spectra 
(number of variants = 3,217) after accounting for base composition differences between the 
chromosomes (Methods, Supplementary Figure 5). This confirms our observation above 
that despite the differences in mutation rates, numbers of genome divisions and cellular 
contexts, the mutation spectra in the maternal and paternal germline are very similar.
To investigate the contribution to germline mutation of 30 previously identified and 
validated mutational signatures operative in somatic lineages leading to cancer16, we 
characterised higher-resolution mutational spectra. For this, we calculated the relative 
frequency of mutations at the 96 triplets defined by the mutated base and its flanking base on 
either side (Figure 5A). The spectrum observed for germline mutations clearly recapitulates 
the known higher mutability of CpG dinucleotides.
We evaluated if any combination of the 30 previously identified signatures16 is sufficient to 
explain the observed pattern of germline mutations (Figure 5B). Two of the mutational 
signatures, previously termed Signatures 1 (25% of DNMs) and 5 (75% of DNMs), explain 
the majority of the observed mutational pattern (Pearson correlation = 0.98; Figure 5C). 
Including any additional mutational signatures did not significantly improve this correlation. 
Signature 1 is characterised by C:G>T:A mutations at CpG dinucleotides, while Signature 5 
is predominately characterised by T:A>C:G mutations (Supplementary Figure 6). These 
signatures are responsible for the generation of the majority of spontaneous pre-neoplastic 
somatic mutations16, indicating that the mutational processes underlying these signatures in 
somatic cells are also operative in the germline.
Methylated CpG sites spontaneously deaminate, leading to TpG sites and increasing the 
number of C:G>T:A mutations21. To test whether methylation status in the germline has a 
detectable impact on mutations, we obtained cell-line methylation data for three cell types 
that had been generated by reduced representation bisulfite sequencing as part of the 
ENCODE project22. In the testis cell-line, 25.3% of CpG sites had more than 50% of reads 
methylated (Supplementary Table 4). 13 of those sites overlap with DNMs from our 
catalogue, of which 12 have more than 50% of reads methylated. This means that in the 
testis cell-line, methylated CpG sites are significantly more likely to mutate than 
unmethylated ones (p = 1.71×10−8, Binomial test). All of the 12 DNMs that were 
methylated in the testis are CpG>TpG mutations (Supplementary Table 5). For B-
lymphocyte and embryonic stem cell-lines, the association between methylation status and 
mutation is less significant (p = 0.04 and p = 2.39×10−6, respectively).
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Discussion
We sequenced the genomes of three multi-sibling families, identified candidate DNMs and 
validated 768 of them by targeted re-sequencing. Both the average genome-wide mutation 
rate of 1.28×10−8, and the ratio of paternal to maternal mutations (3.5) are slightly higher 
than but compatible with previous estimates6. On average, the number of mutations in the 
child increased approximately linearly by 2.9 additional mutations with each additional year 
in the parents’ age. The magnitude of this effect differed by a factor of >2-fold between 
families. While our observations corroborate a previous study6 that proposed that the major 
factor influencing the number of mutations in a child rate is paternal age, our multi-sibling 
study design allows detection of more subtle differences between families. Given that the 
increase in mutations with parental age is driven by paternal mutations, we suggest that this 
observation could result from variation between males either in the rate of turnover of 
spermatogenic stem cells, or in the mutation rate per cell division. A recent review noted that 
the strength of the paternal age effect differs between studies23. Whilst this could be due to 
study design or analysis choices, our results highlight a more interesting possibility, namely 
that, due to the families in each study, the paternal age effect actually differed between the 
studies, most of which had a limited sample size.
We observed no difference in mutation spectra between the maternal and paternal germlines 
or between young and old fathers. The lack of large differences in mutation spectra between 
the sexes is perhaps counter-intuitive, given the different cellular contexts in the maternal 
and paternal germline, including the marked difference in cell divisions and thus the 
increased potential for replication-associated mutations in the paternal germline. Larger 
catalogues of paternal and maternal mutations will be required to identify any subtler 
differences in germline mutation spectra.
We have shown that a combination of two previously identified mutational signatures 
operative in somatic cell lineages are sufficient to explain the observed mutational spectrum 
of germline mutations. These two mutational signatures were originally extracted from 
somatic mutations derived from diverse cancer genomes and thus likely reflect mutation 
processes operative across somatic tissues16. This high concordance between the germline 
and the soma suggests that the mutation processes underlying these two signatures are 
associated with maintenance and replication of DNA in all cells. The generality of these two 
signatures, and their underlying mutation processes, across diverse cellular contexts, likely 
explains our observation of an absence of appreciable age- or sex-dependent variation in 
mutation spectrum. Nonetheless, despite this genome-wide concordance across different 
cellular lineages, our observation of increased mutation rate at sites known to be methylated 
in a testis-derived cell-line revealed that DNA methylation, and perhaps other cell-type 
specific factors, has a finer-grained role to play in influencing the precise location of 
mutations in specific cell-types.
With regard to the timing of mutations in the cellular lineage of the germline, we have 
shown that at least 3.8% of DNMs are mosaic in at least 1% of parental blood cells. This 
estimate represents a lower bound on the true proportion of DNMs that are mosaic in 
parental somatic tissues, as we only sampled a single somatic tissue and cannot exclude the 
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possibility of very low level (<1%) mosaicism in that tissue. This proportion is compatible 
with a recent estimate for parental somatic mosaicism of copy number variants24. We infer 
that DNMs that are mosaic in parental soma must have arisen early on during embryonic 
development of the parent (first 8-12 cell divisions 25,26), prior to the specification of 
primordial germ cells (PGCs) and the concomitant separation of the germline from the 
soma. Whereas all DNMs showed a 3.5:1 ratio of paternal to maternal mutations, these early 
mutations were compatible with a 1:1 ratio of paternal and maternal origins, as might be 
expected given the origin of these mutations prior to sexual differentiation of the embryo.
We note that our observations are not compatible with monophyletic origins of blood and 
germline, but that each tissue must be founded by multiple cells with polyphyletic ancestry. 
A logical consequence is that some mesoderm founder cells are more closely related to 
primordial germ cells within the cellular genealogy of the early embryo than they are to 
other mesoderm founder cells, and vice versa.
One limitation of our study is not having complete ascertainment of all pre-PGC mutations. 
Mutations that arose in very early post-zygotic divisions may well be present at such high 
frequencies within parental tissues that our analytical workflow for identifying candidate de 
novo mutations fails them on the basis that such sites are much more likely to be inherited 
variants with a biased sampling of alleles. Moreover, pre-PGC mutations that arose in later 
cell divisions, only just before PGC specification, may be mosaic in parental somatic tissues 
at such low levels that our deep resequencing was unable to identify them. Nonetheless, the 
20-fold difference in levels of somatic mosaicism that we could detect suggests that we were 
able to detect pre-PGC mutations across at least 4 rounds of early embryonic cell division 
(24 < 20).
Using the data we have generated on the paternal age effect and the prevalence of parental 
somatic mosaicism, we can interrogate the mutagenicity of different phases of 
gametogenesis. By assigning mutations to early embryonic cell divisions prior to PGC 
specification, we can estimate a credible range for the mutation rate in early cell divisions in 
parental germlines. Based on the sharing of pre-PGC mutations between gametes from the 
same parent, we can define a maximal and minimal number of pre-PGC cell divisions within 
which the observed pre-PGC mutations must have occurred, and from these estimate an 
upper and lower bound on the mutation rate per cell division. Our data suggest that the pre-
PGC mutation rate per cell division is in a range of ~0.2 to 0.6 (for a haploid genome) in 
both parental germlines). The paternal age effect that we observed implies that a lower 
mutation rate per cell division of a range of ~0.09 to ~0.17 (~2-4 paternal mutations per year 
derived from 23 cell divisions) operates during post-pubertal spermatogenesis. By contrast, 
oogenesis appears to be significantly more mutagenic than post-pubertal spermatogenesis 
with a mutation rate per cell division of ~0.5 to ~0.7 (~10-14 maternal mutations arise 
during ~20 post-PGC cell divisions27). In the paternal germline, we also need to consider an 
intermediate phase of cell division, during the proliferation and differentiation of PGCs to 
form pre-spermatogonia during prenatal development. This phase of spermatogenesis is 
contemporaneous with oogenesis in females. By extrapolating the paternal age effect we can 
estimate the total number of paternal mutations at puberty (averaging across pedigrees and 
assuming no maternal age effect) to be ~19, and by subtracting the number of pre-PGC 
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mutations (~2-6, from ~10 divisions), we can estimate the number of paternal mutations that 
arose during this intermediate phase to be ~13-17. It has been estimated that there are ~24 
cell divisions during this phase27 giving a range of mutation rate per cell division of 
~0.5-0.7, very similar to that observed during maternal PGC proliferation and differentiation 
to oogonia.
From these observations we derive a tentative model of germline mutation rate during 
gametogenesis (Figure 6), with two phases of oogenesis and three phases of 
spermatogenesis, wherein the mutation rate per cell division is higher during early 
embryogenesis and during PGC proliferation and differentiation during later embryogenesis, 
and reduces ~3-fold during post-pubertal spermatogenesis. This model is consistent with 
prior inferences that the average mutation rate per cell division must be higher in the female 
germline given the relative number of cell divisions and the ratio of paternal and maternal 
mutations, and this could be due to a lower error rate per cell division after puberty in 
males 23. It has previously been suggested that the earliest embryonic divisions exhibit 
elevated mutagenicity with respect to structural variation28. Our data suggest that for SNVs, 
the main step change in mutation rate per cell division may be between embryonic and post-
pubertal phases of gametogenesis in males, and a similar observation has been reported in 
mice spermatogenesis29. If the model that we have proposed above proves to be correct, then 
it suggests that evolutionary selection may have acted to lower the mutation rate per cell 
division during post-pubertal spermatogenesis, perhaps achieving a selective balance 
between producing sufficient numbers of sperm to maintain fertility, while minimizing the 
deleterious mutation rate.
It is important to note that the estimated ranges for the mutation rate per cell division 
presented above represent a combination of mutations that arise during genome replication 
and any spontaneous mutations between cell divisions. The time interval between cell 
divisions differs markedly throughout the different phases of gametogenesis, and so these 
mutation rate estimates do not necessarily reflect the mutagenicity of genome replication in 
isolation.
We infer that germline DNMs that are mosaic in parental soma will also be mosaic in the 
germline, indeed we observed that the six parental somatic mosaic DNMs that were shared 
among siblings had significantly higher levels of somatic mosaicism, on average, than the 
other parental somatic mosaic DNMs that were not shared between siblings (p=0.009, 
Mann-Whitney test). This suggests that the extent of somatic mosaicism correlates with the 
extent of germline mosaicism, and hence the probability that a DNM will be observed 
recurrently among siblings.
We identified four DNMs that were shared among siblings, and thus are highly likely to be 
mosaic in the parental germline, although we observed no evidence for accompanying 
somatic mosaicism in parental blood. We infer that these mutations may have arisen in early 
cell divisions post-PGC specification and thus mosaicism is restricted to the germline.
Previous studies of germline mosaicism of sequence variants have been largely limited to 
case studies of sibling recurrence of pathogenic DNMs30-34. Our 1.3% estimate of the 
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average recurrence probability is compatible with those empirical studies, but they are not 
compatible with recent lower estimates of recurrence risks derived from theoretical 
modeling of the cellular genealogy of the germline35. We note that these recurrent DNMs 
between siblings were not randomly distributed between families, but were significantly 
enriched in one pedigree. This suggests that there may also be significant variation between 
families in patterns of germline mosaicism of DNMs.
These results on germline mosaicism have implications for the genetic counselling of 
recurrence risks for families with children with genetic disorders caused by DNMs 17. While 
the currently used recurrence risk of ~1% is supported by our findings, our data suggest that 
this represents an average across DNMs with very different recurrence risks. While only 
1.3% of all DNMs were observed recurrently among siblings, this increases to 24% for 
DNMs that were mosaic in >1% of parental blood cells and 50% for DNMs mosaic in >6% 
of parental blood cells. Our data suggest that deep sequencing of parental blood for 
pathogenic DNMs seen in children should enable meaningful stratification of families into a 
substantial majority with <1% recurrence risks, and a small minority with recurrence risks 
that could be at least an order of magnitude higher. Considerably more data will be required 
to enable more precise quantitative estimates of recurrence risks given an observed extent of 
parental somatic mosaicism.
Our data also show that in the absence of deep sequencing of parental somatic tissue(s), 
knowing the parental origin of DNM alters the recurrence risk, with maternal mutations 
likely having a ~3 to 4-fold higher recurrence risk, on average, than paternal mutations. As 
noted previously24, the higher probability of germline mosaicism for maternally-derived 
DNMs results in a higher recurrence risk, on average, for DNMs causing X-linked recessive 
disorders than for autosomal dominant disorders.
Pedigree based analyses always are limited by the number of offspring available. Deep 
sequencing of single gametes from different individuals36 should enable us to characterise 
and compare their mutation rates and spectra at much higher resolution. This will also 
mitigate any biases associated with the selection inherent during conception and fetal 
development, although it would still be prone to biases caused by mutations that confer 
enhanced proliferation on progenitors of gametes12. Moreover, sequencing progenitors of 
gametes from different stages of the germline would illuminate our current limited 
understanding of the selective pressures operative throughout the genealogy of the germline.
Online methods
We conducted a study of genome-wide germline mutations by sequencing the genomes of 
three healthy families who participated in the Scottish Family Health Study (SFHS). 
Informed consent was obtained from all participants. The families were selected based on 
genomic DNA quality, the number of children, and the age gap between the oldest and 
youngest sibling.
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De novo mutation discovery
For each of the three families, the two parents and children were sequenced to 24.7× 
coverage on average. In one of the families (Family 569), a child of one of the proband was 
also sequenced. We used the DeNovoGear software1 to identify 49,893 candidate DNMs in 
the children. We identified likely false positives as those sites that overlapped low 
complexity regions2, which we defined as segmental duplications or simple repeats. Further, 
we removed sites that had more than 5% of reads supporting the alternative allele in either of 
the parents. To avoid regions with a large number of misaligned reads, we also removed sites 
whose depth was in the top 0.01% quantile in terms of read depth. For this, we assumed read 
depth to be Poisson-distributed, with the lambda parameter of the Poisson distribution being 
equal to the mean read depth of the genome. Taken together, these filters resulted in 4,881 
candidate sites.
For validation, we designed Agilent SureSelect probes around the sites that passed filtering 
and resequenced the resulting pulldown library using Illumina to 139× coverage on average 
(range: 88-191). We designed baits to cover a 200bp window around the candidate sites. The 
bait design succeeded for 4,141 sites. To analyse the validation data, we classified each 
putative DNM into one of three categories: Germline DNM, inherited variant or false 
positive and evaluated the likelihood of the data under each model. The three models are 
defined below. In addition, 37 of the DNMs were removed following manual inspection in 
the IGV genome browser.
Model 1: Germline DNM—We defined the likelihood of the data under the DNM model 
as:
mm, dm, and cm are the number of reads supporting the mutant allele (mostly the alternative 
allele) in the mother, the father and the child, respectively. mT, dT, and cT are the total 
number of reads in the mother, the father and the child, respectively. e is the sequencing 
error rate.
Model 2: Inherited variant—The likelihood that the variant is inherited is defined as:
LL.IFM, LL.IFD, and LL.IFMD refer to the likelihood that the variant is maternally 
inherited, paternally inherited, or inherited from both parents:
Model 3: False positive—
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Correction of the mutation rate
The correction accounts for the part of the genome that we could not interrogate because of 
insufficient depth in low complexity regions, filtering procedures to exclude false positives, 
and failed validation. To take into account the different karyotypes of the male and female 
genomes, the precise form of the correction depend on the sex of the proband:
noCvg is the proportion of the genome that is either N or not covered at 7x or more, filtered 
is the proportion that is a segmental duplication or a simple repeat (but not N or low 
coverage), noVal is the proportion that passed filtering but for which validation was not 
possible (mainly due to failed primer design), ppAdjust is the proportion of non-validatable 
calls that are likely to be true positives based on their posterior probability as calculated by 
DeNovoGear, valDNM is the number of validated DNMs, valDNMX is the number of 
validated DNMs on the X chromosome, and genomeLength is the length of the human 
reference genome build 37 without the Y chromosome, unmapped regions, and 
mitochondrial DNA. This correction assumes that the mutation rate is similar in the 
inaccessible regions of the genome. On average, 83.1% of the genome was accessible, 
ranging from 82.1% to 84.3% in different genomes.
Identification of DNMs mosaic in parents
We used two analytical methods to identify potential parental mosaic DNMs in our multi-
sibling family sequencing data: DNMs shared among siblings and DNMs with excess 
alternative reads in DNA from one parent.
Method 1: Identification by recurrence in siblings—Only validated and therefore 
high confidence DNMs, were used for this analysis. Validation ensured that the DNMs were 
not constitutively heterozygous in either parent. This method involved the identification of 
DNMs that were present in more than one offspring from the same family.
Method 2: Identification by excess of alternative reads in a parent—Potential 
parental germline mosaic events were further investigated in the 768 validated DNMs by 
identifying instances of a significant excess of reads supporting the alternative allele in one 
of the parents. To improve our power to detect candidate germline mosaic sites, we 
performed an additional Miseq run of the custom pull down library we previously used for 
validation, which resulted in an average coverage of 500X for validated DNMs (n=768). The 
site-specific error rate for each DNM was estimated by dividing the total number of reads 
supporting the alternative allele by the total number of reads in all non-related individuals, 
from the two families, in which the DNM was not discovered. Hence the probability that the 
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observed number of parental ALT alleles resulted from sequencing error was calculated as 
follows:
Where m and f are the number of reads in the mother and father respectively, alt and ref are 
the alternate and reference alleles respectively, and e is the site-specific error rate. Both 
maternal and paternal p values for each DNM were adjusted for multiple testing using the 
Bonferroni correction. Sites that were significant at an adjusted p< 0.05 were considered as 
mosaic. In total, 24 mosaic sites were validated using this method. Six of these were also 
discovered by the sibling recurrence method described above.
Estimation of recurrence risk—The probability of an apparent DNM being shared 
between more than one sibling in the same family was calculated as number of instances of a 
mutation being shared between two siblings divided by the number of pairwise comparisons 
between two siblings, in all three families (Supplementary Table 2).
Validation of DNMs mosaic in parents
We carried out further independent validation of 40 candidate parental mosaic DNMs 
( method 1 and 2, Supplementary table) using PacBio amplicon sequencing. These 40 
candidate mosaic DNMs were selected as follows: 10 DNMs that were shared between 
siblings (for six of these shared DNMs we had previously identified a significant parental 
excess of alt alleles, as described above), and 30 candidate mosaic sites that had an excess of 
alt alleles in a parent’s blood, with a nominal p value <0.05 . Note this set of 30 candidates 
was based on nominal significance rather than Bonferroni corrected significance and so 
represents a less stringent set of candidate mosaic DNMs.
Primers were designed using Primer 33 in order to generate amplicons with an average 
length of 250 bp, with the candidate mosaic site in the middle of the amplicon. For each 
candidate mosaic site, amplicons were prepared for the mosaic children and their parents, 
including a unique 11 bp sequence in the forward primer to act as a barcode for each 
individual. The amplicons were prepared using a standard PCR protocol. Two of the 
candidate mosaic sites (chr2: 37841931, and chr4: 131248301) failed to amplify and 
therefore were not included in this validation experiment.
In total 114 amplicons were successfully prepared for the remaining 38 sites. Amplicons 
were pooled in equimolar amounts and prepared for circular consensus sequencing with 
shared libraries on PacBio SMRT cell.
Following PacBio sequencing, the filtered subreads and ROI (reads of insert) were generated 
using SMRTAnalysis (provided by Pacific Biosciences, Menlo Park CA). The resulting fastq 
files were demultiplexed based on the 11bp unique barcodes for each individual and mapped 
to the human reference genome GRCh37 (hg19). Average sequence coverage from the 
PacBio data was 158X across the 114 amplicons. Lastly, variants were called from the 
resulting BAM alignments using samtools4 mpileup, version1.1. Each of the candidate 
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parental mosaic DNMs were only further analysed if we observed ~50% ref/alt in the child, 
and hence their parental alt/ref were counted. We categorised sites with this criteria into: 1-
Validated, comprising sites where we observed alternative alleles in the relevant parent, 2-
Uncertain, comprising sites where we had <90% power to detect the alternative alleles in the 
parents (PacBio detection power was calculated using the mosaicism level from the Miseq 
data), and finally 3-Not validated, comprising sites where we had>90% power to detect the 
alternative allele in the mosaic parents but failed to detect them.
We classified 29 of the 40 candidate sites set as parentally mosaic. Four mosaic DNMs were 
shared between the siblings in the same family but we could not observe alternative alleles 
in either parent in either validation dataset (Miseq and PacBio). 16 sites were validated as 
mosaics where the mosaic parent was confirmed on both platforms (all of these sites had 
significant p-value for their Miseq data after the Bonferroni correction). One additional site 
with significant nominal p-value but not significant adjusted p-value for the Miseq data was 
confirmed mosaic on PacBio. Two sites were confirmed as mosaic based on significant 
adjusted p-value from the Miseq only, as they failed the PacBio experiment. Six sites were 
confirmed mosaic based on Miseq only (with significant adjusted p-values), as their 
mosaicism level was below detection power on PacBio. In the remaining 11 sites, despite 
having significant nominal p-values, the adjusted Miseq p-value was not significant and the 
PacBio data was inconclusive (Table 1 and Supplementary table).
In summary, we attempted further experimental validation of 40 candidate mosaic sites by 
conducting deep amplicon sequencing (158X mean coverage per individual) in the child, 
mother, and father’s blood using the PacBio platform. This validation experiment confirmed 
the presence of ALT reads in parental blood-derived DNA at 100% of DNMs (N=9) where 
the PacBio data had >90% power to detect the level of mosaicism observed in the MiSeq 
data. Furthermore, we observed 100% concordance (N=14) between the parental-origin 
determined by significant excess of ALT reads in maternal or paternal blood and that 
determined by phasing the DNM onto a parental haplotype.
Correction for mosaic power detection
In order to estimate the number of mosaic sites that we failed to detect due to power 
limitations, we ran 1000 simulations across our 768 validated de novo mutations with their 
given coverage (from Miseq sequencing) for a range of mosaicism levels. We calculated the 
number of sites with >2% mosaicism that we failed to identify. For this we defined two bins 
for the mosaic level (2%-4%, >4.0%). The average undetectable mosaic sites were 
calculated as a product of number of mosaic sites and average detection power for each bin. 
Hence, the number of germline mosaics after power adjustment is ~4% (31/768) of validated 
de novo mutations.
Parent of origin
To study the effect of parental age and sex on germline mutations we determined the 
parental origin for the validated germline DNM using three approaches.
Firstly, we used DeNovoGear’s readpair algorithm1 to obtain parental phasing information. 
In short, this algorithm determines the parent of origin if haplotype informative sites are 
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present in phase with the mutation in the child and in the parents. The informative sites are 
those that are phased with respect to the mutation in the child because they are located on 
the same read pair. Furthermore, the genotype of the site must be informative in the parents. 
Using this method, we identified an informative haplotype for 198 mutations.
Secondly, a child of one of the probands (SFHS5165328 in Family 569) was also sequenced. 
For this proband, the parent of origin was determined using informative variants in a 20 kb 
window around the DNM. If the paternal haplotype was transmitted to the proband and the 
child also carried the DNM, then the mutation was classified as being of paternal origin. 
Similarly, if the child carrying the paternal haplotype did not have the DNM, then the 
mutation was classified as being of maternal origin. The same logic was applied when the 
child inherited the maternal haplotype of the proband. Using this method, we identified an 
informative haplotype for 30 mutations.
Thirdly, we experimentally ascertained the parental haplotype on which the DNM arose. 
Genomic DNA from the child was diluted to single molecule concentration and then re-
amplified across 48 wells using Repli-G Midi Kit from Qiagen. The resultant amplified 
DNA, along with undiluted genomic DNA from the child and the parents, was then 
Sequenom genotyped at the putative DNM of interest, along with the nearest haplotype 
informative SNP (heterozygous in the child, and heterozygous in one of the parents). If 
genotyping assays were heterozygous in child, homozygous in parents at the putative DNM 
in the unamplified DNA, and homozygous in the single molecule amplified wells, then the 
raw genotype data from the 48 amplified single molecules was analyzed in two ways. Firstly, 
haplotype inference was obtained from examining peak height correlations between the 
genotype calls for the putative DNM and adjacent informative SNP, and clustering of calls 
was observed using an in-house script. Secondly, genotype calls (or peak heights pertaining 
to genotype calls) from the same well were counted for each locus and the haplotype derived 
from a likelihood ratio test as detailed by Konfortov et al.5
Mutational catalogue
We generated a catalogue of human DNMs based on previously published high confidence 
mutations obtained by whole genome sequencing (Supplementary Table 3). Only single 
nucleotide DNMs were included. Where necessary, we used the LiftOver tool to convert 
coordinates from NCBI build 36 to build 37.
Mutational spectra and signatures
Mutational spectra were derived directly from the reference and alternative (or ancestral and 
derived) allele at each variant site. The resulting spectra are composed of the relative 
frequencies of the six distinguishable point mutations (C:G>T:A, T:A>C:G, C:G>A:T, 
C:G>G:C, T:A>A:T, T:A>G:T). Significance of the differences between mutational spectra 
was assessed by comparing the number of the six mutation types in the two spectra by 
means of a Chi-squared test (df = 5).
Mutational signatures were detected by refitting of previously identified consensus 
signatures of mutational processes6. All possible combinations of at least seven mutational 
signatures were evaluated by minimizing the constrained linear function:
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Here,  and  represent vectors with 96 components 
corresponding to the six types of single nucleotide variants and their immediate sequencing 
context and Exposurei is a nonnegative scalar reflecting the number of mutations contributed 
by this signature. N reflects the number of signatures being re-fitted and all possible 
combinations of consensus mutational signatures for N between 1 and 7 were examined, 
resulting in 2,804,011 solutions. Model selection framework based on Akaike information 
criterion was applied to these solutions to select the optimal decomposition of mutational 
signatures.
Diversity and divergence data
Diversity data was based on 2,453 individuals who were whole genome sequenced to 6-8× 
depth as part of the ALSPAC and Twins UK cohorts within the UK10K project. Ancestral 
alleles were defined by a maximum parsimony approach as those that appeared in most of 
five ape species (human, chimp, gorilla, orang-utan, macaque)7. Processing of great ape 
reference genome data is described below. Single nucleotide variants were determined to be 
equivalent to one of the six mutation types according to the identity of the ancestral and 
derived alleles.
Using an approach that was identical to that taken by others8, variant sites that were likely to 
be under selection because they were located in exonic regions or because they were 2kb 
upstream or downstream of genes were filtered and excluded from the dataset. To avoid 
biases created by misalignment of sequencing reads, we also excluded sites that overlapped 
simple sequence repeats or segmental duplications. Where DNMs were compared to 
variants, they were subjected to the same filters.
Divergence data was based on multispecies alignments of the chimpanzee, gorilla, orang-
utan, macaque and human reference genomes, as provided by Ensembl Compara. Sites 
likely to be under selection were removed in the same way as described for the diversity 
dataset. Sites that were different in humans compared to the other great ape species were 
defined as substitutions.
Sex chromosomes
We included only the rarest 5% of variants into this analysis, as the spectrum of those 
variants most resembles that of DNMs, as we show elsewhere in this study. From the 
resulting variants, we obtained raw mutational spectra for each chromosome, as well as 
mutational spectra corrected for chromosomal nucleotide composition. The correction for 
chromosomal nucleotide composition was done by counting the number of each of the four 
nucleotides in the interrogated regions of each chromosome. For each variant, we 
determined the ancestral and the derived allele. For each variant type, we then divided the 
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number of variants by the number of nucleotides that matched the ancestral allele 
(Supplementary Figure 5).
Methylation data
We downloaded ENCODE methylation data from the UCSC server for three cell-lines: 
BC_Testis_N30 (testes of a 41-year old Asian donor), GM12878 (B-lymphocytes from a 
European Caucasian donor), and H1-hESC (embryonic stem cells). The methylation data 
had been obtained by reduced representation bisulfite sequencing (RRBS). For each cell-
line, two replicates were available. We only included sites that were represented in both 
replicates. There were 1,151,596 such sites in BC_Testis_N30, 1,048,775 in GM12878, and 
1,118,911 in H1-hESC. For each cell-line, we identified sites with more than 50% of reads 
were methylated in both replicates combined. We also identified sites that were present in 
our DNM catalogue. We computed binomial p values as as Bin(q, n, p), where q is the 
number of methylated DNMs, n the total number of DNMs for which methylation data is 
available, and p the proportion of sites that are methylated in the dataset.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Pedigrees of sequenced families
Identifiers and relationship between the individuals in the three families in this study. 
Individuals that were sequenced are symbolised by full circles and squares, other individuals 
by dotted circles and squares. Age of mother and father at the conception of each child and 
phasing information are summarised in the table. SFHS5165321 was only used for the part 
of the analysis related to mosaicism.
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Figure 2. Paternal age vs. number of de novo mutations
The number of DNMs has been corrected to take into account genomic regions inaccessible 
to our methods. Red: Family 244. Yellow: Family 569. Blue: Family 603. Gray areas denote 
the regions covered by the 95% confidence interval of the intercept and slope of the linear 
regression line for each separate family. We note that the confidence intervals for families 
244 and 603 do not overlap for younger fathers.
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Figure 3. Detection of mutations mosaic in parents
(A) Simulation of detection power for ranges of mosaicism levels in the parents blood using 
the Miseq depth of coverage for all the de novo mutations (n=768). For mean validation 
coverage (Miseq platform) of 567X in the parents, we have >0.94 power to detect mosaicism 
of 2% and higher in the parents blood. (B) Comparison of parental Alt ratios between de 
novo mutations vs. germline mosaic sites. M is mosaic sites with significant excess of alt in 
the mother’s blood, P is the sites with significant excess of alt in the father’s blood, S is 
corresponding to the sites that are shared between the siblings but we could not detect any 
excess of alt allele in the either of the parents blood. SM/SP refer to the mosaic sites that are 
shared between the siblings and we have detected significant excess of alt in the mother’s 
blood (SM presented in pink dots) or father’s blood (SP shown in dark blue dot).
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Figure 4. Mutational spectra
(A) Frequency of all mutation types in the catalogue of 6,570 high confidence DNMs (B) 
Difference in the frequency of maternal and paternal mutations for the subset of DNMs with 
phasing information (n=556) (C) Difference in the frequency of mutations of children 
fathers younger and older than 30 years (n=680). Error bars represent 95% confidence 
intervals.
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Figure 5. Mutational spectrum and signatures
(A) High resolution mutational spectrum of de novo mutations. Each of the six possible 
point mutations is subdivided into 16 subclasses based on the 3′ and 5′ nucleotide flanking 
the mutation. We note that C:G>T:A and T:A>C:G transitions are more common. Within 
those categories, CpG sites are particularly frequent (B) Correlation of mutational signatures 
with observed mutations in mutational catalogue, correlation of each of the 30 signatures, 
with signatures 1 and 5 highlighted in orange (C) Combination of all possible pairs of 
signatures, with the combination of signatures 1 and 5 shown with an arrow.
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Figure 6. Mutation rate model during gametogenesis
Comparison of mutation rate between spermatogenesis (blue-box) vs. oogenesis (red-box). 
μp and μm are mutation rate in paternal and maternal genome in respective order and 
mutation rate per each stage of gametogenesis is denoted by number. Gametogenesis is 
divided into three stages with different ranges of mutation rates. Stage 1: Pre-PGC 
specification (8-12 cell divisions in both maternal and paternal germline) ~0.2-0.6 mutations 
per haploid genome per cell division and this rate is the similar in both maternal and paternal 
gametogenesis, stage 2: post-PGC specification, in maternal germline there are ~20 cell 
divisions, in paternal germline there are ~24 cell divisions post-PGC up to puberty, mutation 
rate is similar at this stage in both sexes, (~0.5-0.7 mutations per haploid genome per cell 
division). Stage 3: post-puberty (only applicable to the paternal germline) sperm are 
continuously produced through the asymmetric division of self-renewing spermatogonial 
stem cells with ~23 cell divisions per year. The mutation rate falls to a range of ~0.09 to 0.17 
mutations per haploid genome per cell division. This model is tentative and does not yet take 
all possible sources of uncertainty into account.
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